Find out the best timing in the update to the Protein Powders, Drinks, and Shakes Review
Researchers studying optimal treatment duration for GLP-1 therapies will find this particularly relevant
Sergey Terushkin, MD, FACS One of the biggest misunderstandings is confusing the return of an old injury with withdrawal
Today peptides, tomorrow homeopathy (...though at least for the latter, a presumption of safety would have a more rational basis) Eric, what feels especially important here is that the difficult question is not only whether a biological signal exists, but whether the strength of evidence matches the level of confidence required for clinical use
Confirmatory secondary endpoints included additional HbA 1c comparisons and relative change in bodyweight (%) from baseline to week 68
Subcutaneous and intraperitoneal routes achieve 6090% bioavailability, while intranasal delivery offers higher CNS-specific bioavailability (3060%) with lower systemic exposure
